J Biol Chem, Vol. 274, Issue 42, 30209-30214, October 15, 1999
Post-transcriptional Regulation of H-ferritin mRNA
IDENTIFICATION OF A PYRIMIDINE-RICH SEQUENCE IN THE
3'-UNTRANSLATED REGION ASSOCIATED WITH MESSAGE STABILITY IN HUMAN
MONOCYTIC THP-1 CELLS*
Li-Shaung
Ai and
Lee-Young
Chau
From the Division of Cardiovascular Research, Institute of
Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C
 |
ABSTRACT |
We have previously demonstrated that phorbol
myristate acetate (PMA) up-regulates H-ferritin gene expression in
myeloid cells by stabilization of its message. In the present report,
we showed that insertion of the 3'-untranslated region (3'-UTR) of
H-ferritin mRNA at the 3'-end of luciferase coding sequence
significantly reduced the stability of luciferase mRNA in human
monocytic THP-1 cells. However, the half-life of the chimeric
transcript was markedly prolonged after PMA treatment. A cytosolic
protein factor from THP-1 cells was found to specifically bind to
H-ferritin 3'-UTR. PMA treatment of THP-1 cells resulted in the
reduction of the RNA binding activity in a time-dependent
manner. Deletion analysis and RNase T1 mapping revealed a
pyrimidine-rich sequence within the 3'-UTR which interacts with the
protein factor. Competition experiments with homoribopolymers further
demonstrated the importance of uridines for the binding activity. Point
mutations in uridines of the pyrimidine-rich sequence reduced the
protein binding to 3'-UTR, while increasing the stability of the
chimeric luciferase transcript. Together, these results demonstrate
that the pyrimidine-rich sequence in the 3'-UTR is involved in
post-transcriptional regulation of H-ferritin gene expression in
myeloid cells.
 |
INTRODUCTION |
Ferritin is a multimeric protein with a function in controlling
the iron homeostasis in cells (1, 2). In mammals, each ferritin
molecule consists of 24 subunits of two types, heavy (H)1 and light (L), which are
derived from distinct genes and share only about 50% homology in amino
acid sequences. It is generally believed that H-ferritin, which
contains a ferroxidase activity (3), plays a key role in the
intracellular flux of iron, whereas L-ferritin is primarily responsible
for the iron storage. H- and L-ferritin combine in variable ratios in
different cells or tissues depending on the cellular requirement for
iron as well as the differentiation or pathological states. The
synthesis of H- and L-ferritin can be regulated by iron at the
translational level (1, 2). When the intracellular iron concentration
is low, a repressor protein would bind to a conserved iron regulatory element located in the 5'-untranslated regions of H- and L-ferritin mRNAs to inhibit the translation of both genes (4-6). Increased iron concentration will lead to the dissociation of the repressor from
the iron regulatory element and result in the increase of ferritin
synthesis. In addition, early studies have demonstrated that L- and
H-ferritin genes are subjected to differential regulation during
development, cellular differentiation, or inflammation, although the
molecular mechanisms are not fully resolved (7-13). It has been shown
that differentiation of human leukemia cells leads to an increase in
the H/L ratio of ferritin expression (14, 15). Using the human
monocytic THP-1 cell line as a model system, we have demonstrated that
phorbol myristate acetate (PMA)-induced differentiation of THP-1 cells
toward macrophages markedly up-regulates the expression of H-ferritin
mRNA, but not L-ferritin mRNA, in a cell-type specific manner
(16). Furthermore, the gene induction appears to be the result of
stabilization of the H-ferritin transcript (16). Since the stability of
most mRNAs has been shown to be regulated by sequences in their
3'-UTRs (17), we hypothesized that an unique cis-regulatory element
within the 3'-untranslated region (3'-UTR) of H-ferritin mRNA is
likely involved in regulating the stability of the H-ferritin message
in PMA-treated THP-1 cells.
In the present study, we identified a pyrimidine-rich sequence within
the 3'-UTR of the H-ferritin mRNA to be associated with the message
turnover in THP-1 cells. Gel-mobility shift assay demonstrated the
existence of a RNA-binding protein in the cytosolic fraction of THP-1
cells to interact with this sequence. PMA treatment down-regulated the
binding of the protein factor to H-ferritin 3'-UTR, suggesting that the
interaction between the cytosolic protein and the cis element serves as
a destabilizing signal to facilitate the degradation of H-ferritin
mRNA in THP-1 cells.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Human monocytic THP-1 cells were grown in RPMI
1640 medium supplemented with 10% (v/v) fetal calf serum. HeLa and
hepatoma PLC cells were grown in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum. Cells were incubated in a
humidified atmosphere of 95% air, 5% CO2 at 37 °C. For
PMA treatment, THP-1 cells were grown to a density of 1 × 106 cells/ml and treated with 100 ng/ml PMA for indicated times.
Plasmid Constructs--
A cDNA fragment spanning the
full-length 3'-UTR of the H-ferritin gene (nucleotides
3 to +150, +1
is the first nucleotide after the stop codon) was obtained by
polymerase chain reaction (PCR) using the human H-ferritin cDNA as
the template (18). EcoRI and HindIII restriction
sites were created in sense and antisense primers, respectively. The
sequences of the sense and antisense oligonucleotides are as follows:
sense, 5'-GACAGTGATAATGAATTCTAAGCCTCGGG-3'; and antisense,
5'-GGGACCAAGCTTCTTTATTTGAAGGAATGG-3'. The PCR fragment was subcloned
into the EcoRI-HindIII site of the pGEM11Zf+
vector (Promega). To prepare the constructs containing the mutated
nucleotides within the sequence located at nuucleotides +72 to +88 of
the 3'-UTR, the sense primers containing mutated nucleotides and the SphI restriction site at the 5'-end were used for PCR. The
sequences of these oligonucleotides are as follows: M1,
5'-GGCAGTGCATGCATGTTGGGGATACCTT-3'; M2,
5'-GGCAGTGCATGCATGTTGGGGATACCATAACCATATCTAT-3'. The PCR was performed
with M1 or M2 sense primer and the antisense primer containing the
HindIII restriction site described above. The PCR fragment
was digested with SphI and HindIII restriction
enzymes and subcloned into the SphI-HindIII site
of digested pGEM11Zf+ plasmid containing the wild type 3'-UTR. To
construct the luciferase/3'-UTR chimeric plasmid, a cDNA fragment
containing luciferase coding sequence was prepared by PCR using
pGL2-Basic plasmid DNA as the template. The sequences of the primers
used are as follows: sense, 5'-GATCTAAGTAAGCTTGGCATTCCGGTACTG-3';
antisense, 5'-CGCTGGATCCAGTTACATTTTACAATTTGG-3'. The PCR fragment was
subcloned into the HindIII-BamHI site of the
mammalian expression vector, pcDNA3, to generate pcDNA3-Luc. The cDNA fragment of wild type or mutant 3'-UTR with
XhoI and ApaI restriction sites created at the
5'- and 3'-ends, respectively, was prepared by PCR and subcloned into
the XhoI-ApaI site of pcDNA3-Luc to generate
wild type or mutant pLuc-HF-3'UTR.
Transient Transfection and RT-PCR--
THP-1 cells (2 × 107) were transfected with 2 µg of pcDNA3-Luc or
pLuc-HF-3'UTR plasmid DNA using Effectene reagent (Qiagen) according to
the manufacturer's instructions. After incubation in culture medium
for 24 h, cells were divided into 4 dishes and each dish was
treated with 10 µg/ml actinomycin D for indicated times. Total RNA
was then isolated and the expression level of luciferase mRNA was
quantified by RT-PCR. Briefly, 1 µg of total RNA was reverse
transcribed into cDNA by incubation with 200 units of Maloney
leukemia transcriptase (Life Technologies, Inc.) in 20 µl of reaction
buffer containing 10 units of RNasin, 0.2 µg of random hexamers, and
0.8 mM dNTPs at 37 °C for 1 h. Reaction was
terminated by heating at 95 °C for 10 min and the mixture was
diluted to 500 µl with deionized H2O. An aliquot (2.5 µl) was taken for PCR amplification with the primers described above for the preparation of luciferase cDNA. The PCR was performed in 25 µl of 10 mM Tris-HCl, pH 8.3, containing 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, 1 µM of each primer, and 1.25 units
of Taq DNA polymerase. The reaction proceeded for 30 cycles
of denaturation at 94 °C for 1 min, annealing at 50 °C for 1 min,
and extension at 72 °C for 1 min. Amplified cDNA was
electrophoresed on 1% agarose gels containing ethidium bromide. The
cDNA was visualized under UV light and the images were analyzed by
UVP's Gel Base Windows Software.
Preparation of Cytosolic Extracts and Gel Mobility Shift
Assay--
Cells were harvested by centrifugation at 200 × g for 5 min, washed twice with ice-cold phosphate-buffered
saline, and centrifuged again. Cell pellets were resuspended in
ice-cold hypotonic buffer containing 25 mM Tris-HCl, pH
7.9, 0.1 mM EDTA, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, 1 µg/ml leupeptin, and 0.2% Nonidet P-40. After placing on
ice for 5 min, cell lysate was subjected to centrifugation at
100,000 × g for 30 min at 4 °C. The supernatant
(cytosolic fraction) was removed and stored at
70 °C. The protein
concentration was determined by a Bio-Rad protein assay. To prepare the
radiolabeled transcript of the H-ferritin 3'-UTR, the pGEM 11Zf+
plasmid containing wild type or mutant 3'-UTR was linearized by
HindIII restriction enzyme digestion. In vitro
transcription was performed with T7 polymerase in a reaction containing
0.4 mM unlabeled ATP, GTP, CTP, 0.04 mM UTP,
and 30 µCi of [
-32P]UTP (Amersham Pharmacia Biotech,
>3000 Ci/mmol). The 32P-labeled transcript was filtered
through a TE-100 Chroma spin column (CLONTECH) to
remove free [32P]UTP. For the RNA binding reaction,
10-40 µg of cytosolic proteins were incubated with
32P-labeled transcript (30,000-50,000 cpm) in 20 µl of
15 mM HEPES, pH 7.4, containing 1 mM EDTA, 50 mM KCl, 3 mM MgCl2, 10% glycerol, and 10 µg/ml yeast tRNA for 30 min at room temperature. Twenty units
of RNase T1 were added and incubation continued for an additional 30 min, followed by addition of heparin to a final concentration of 2 mg/ml for an additional 10 min. Samples were then subjected to
electrophoresis performed on a 6% native polyacrylamide gel using
0.25 × TBE as electrophoresis buffer. Gels were dried and exposed
to Kodak X-Omat AR films overnight at
70 °C.
RNase T1 Mapping--
Following electrophoresis of the binding
reaction, gel was exposed to x-ray film at 4 °C overnight. The
region of specific RNA-protein complex was identified and excised. The
protected RNA fragment was eluted from gels by electrophoresis through
a NA45 membrane and then recovered from membrane by extraction with high salt buffer. After ethanol precipitation, the recovered RNA was
digested with or without RNase T1 (20 units) at 37 °C for 30 min.
The 32P-labeled 3'-UTR transcript was also subjected to
RNase T1 digestion. The digested products were analyzed by a 12%
polyacrylamide, 8 M urea sequencing gel.
UV Cross-linking--
Following gel-mobility shift assay, the
radiolabeled RNA-protein complex band was excised from the wet gel as
described above. The gel slice was placed on ice and irradiated under a
254-nm UV lamp at a distance of 4 cm for 20 min. The gel slice was then treated with 50 µl of 10 mg/ml RNase A solution at 37 °C for 30 min, followed by the addition of 10 µl of 6 × SDS sample
buffer. After incubation at 37 °C for an additional 30 min, the
entire gel slice was loaded into a 10% SDS-polyacrylamide gel and
analyzed by autoradiography.
 |
RESULTS |
To explore the possibility that the 3'-UTR of H-ferritin mRNA
contains a regulatory element affecting mRNA stability, a chimeric luciferase reporter gene construct carrying the entire H-ferritin 3'-UTR at the 3'-end of the luciferase coding sequence was prepared. After transient transfection into THP-1 cells, the expression of
chimeric luciferase mRNA was assessed by semiquantitative RT-PCR. As shown in Fig. 1, insertion of
H-ferritin 3'-UTR led to the decrease in the half-life of luciferase
mRNA from 8.0 ± 0.5 to 4.5 ± 0.3 h as measured in
the presence of actinomycin D. PMA treatment markedly prolonged the
half-life of the chimeric transcript to greater than 9 h. In
contrast, the half-life of the parental transcript was not
significantly altered by PMA treatment. This result supports the idea
that the H-ferritin 3'-UTR contains a regulatory sequence mediating the
effect of PMA. When the 32P-labeled transcript of
H-ferritin 3'-UTR was incubated with the cytosolic extracts prepared
from monocytic THP-1 cells, followed by digestion with RNase T1, and
analyzed by a native polyacrylamide gel, a RNase-resistant band was
observed (Fig. 2). This band was abolished by the addition of proteinase K or SDS in the binding reaction, indicating that it was formed by the interaction of a protein
factor with the radiolabeled RNA probe. The RNA binding activity was
proportional to the increments of the cytosolic proteins (Fig.
3A). When the radiolabeled
antisense RNA probe was used, there was virtually no binding activity
detected with the same amounts of proteins. The sequence specificity of
the RNA- protein complex was further revealed by the competition
experiment showing that the complex formation was inhibited by the
addition of excess amounts of unlabeled 3'-UTR (Fig. 3C).
Further experiments demonstrated that the RNA binding activity was
barely detectable in the cytosolic extracts prepared from HeLa or
hepatoma PLC cells, indicating that the protein factor binding to the
H-ferritin 3'-UTR is predominantly present in myeloid cells (Fig.
3B). The effect of PMA treatment on the RNA-protein complex
formation was examined. As shown in Fig.
4A, the RNA binding activity
in PMA-treated THP-1 cells was substantially less than that in control
cells. Time course experiments further revealed that down-regulation in
RNA binding is evident at 3 h, reaches a maximum at 12 h, and
is prolonged to 36 h following PMA treatment (Fig.
4B).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 1.
The effect of the 3'-UTR from the H-ferritin
gene on the PMA-induced luciferase mRNA stability in THP-1
cells. A, the 3'-UTR of H-ferritin cDNA was
subcloned into the XhoI-ApaI site next to the
3'-end of the luciferase coding sequence to generate pLuc-HF-3'-UTR.
B, THP-1 cells were transiently transfected with
pcDNA-Luc or pLuc-HF-3'-UTR plasmid DNA as described under
"Experimental Procedures." Transfected cells were pretreated with
or without PMA (100 ng/ml) for 18 h and total RNA was isolated at
different time intervals after treatment with actinomycin D (10 µg/ml) for 0, 3, 6, and 9 h. The level of luciferase mRNA
was quantified by semiquantitative RT-PCR. C, luciferase
mRNA level expressed as a percentage of the initial value was
plotted versus time after actinomycin D treatment. Data
shown are the mean of three independent experiments.
|
|

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Formation of RNA-protein complex between the
3'-UTR of the H-ferritin mRNA and the cytosolic extracts from THP-1
cells. A, the sequence of the 3'-UTR of human
H-ferritin mRNA. The stop codon is double underlined.
The poly(A) signal is underlined. B, the
radiolabeled 3'-UTR was incubated with 20 µg of cytosolic proteins
from THP-1 cells in the absence or presence of proteinase K (2.5 mg/ml)
or SDS (0.1%), followed by RNase T1 digestion and electrophoresis as
described under "Experimental Procedures." Bovine serum albumin (20 µg) was used as a negative control for the binding reaction. The
complex formed is indicated by an arrow. BSA,
bovine serum albumin.
|
|

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 3.
Specificity of the binding activity to the
3'-UTR of H-ferritin mRNA in THP-1 cells. A, the
radiolabeled sense or antisense transcript of H-ferritin 3'-UTR was
used for binding assay with the indicated amounts of cytosolic proteins
from THP-1 cells. B, the RNA binding activity detected in
cytosolic extracts (20 µg) prepared from hepatoma PLC, HeLa, or THP-1
cells. C, inhibition of the RNA binding activity by addition
of indicated amounts of unlabeled the H-ferritin 3'-UTR in binding
reaction. BSA, bovine serum albumin.
|
|

View larger version (54K):
[in this window]
[in a new window]
|
Fig. 4.
Effect of PMA treatment on the RNA-protein
complex formation in THP-1 cells. A, cytosolic extracts
prepared from THP-1 cells treated with (P1 and P2) or without (C1 and
C2) PMA for 18 h were prepared and assayed for the RNA binding
activity. B, THP-1 cells were treated with or without PMA
for the indicated times in culture. Cytosolic extracts (20 µg)
prepared from these cells were then assayed for the RNA binding
activity. BSA, bovine serum albumin.
|
|
To locate the sequence interacting with the cytosolic protein factor,
the 3'-deletion RNA probes were prepared and used for the binding
assay. As shown in Fig. 5, when the RNA
probe prepared from the AflII-digested 3'-UTR cDNA
template was used for binding assay, the RNA-protein complex was still
observed. This complex, however, was not detected by using shorter RNA
probes prepared from the SphI-digested DNA template. This
result indicates that the sequence responsible for the interaction with
the protein factor is located in the region between SphI and
AflII restriction sites in H-ferritin 3'-UTR. This sequence
was further identified by RNase T1 mapping assay. As shown in Fig.
6, digestion of the entire
32P-labeled 3'-UTR with RNase T1, which cleaves after each
G residue, results in oligonucleotides varying from 22 through 2 bases.
When the protected 32P-labeled RNA fragment isolated from
the RNA-protein complex was electrophoresed, it migrated as a 22-base
oligonucleotide. Further digestion of the protected RNA fragment with
RNase T1 did not yield smaller fragments, indicating that the protected
RNA is a G-free sequence located at 72-92 nucleotides downstream of
the stop codon of H-ferritin gene. It was noted that this sequence is
rich in pyrimidines, particularly the uridines. To test whether the U
residues are important for binding with the protein factor, a
competition experiment with various homopolymers of ribunucleotides was
performed. As shown in Fig. 7, the
formation of the RNA-protein complex could be completely inhibited by
excess amounts of poly(U) homopolymers but not by poly(C) or poly(A),
supporting that the poly(U) tract is essential for the binding
activity.

View larger version (47K):
[in this window]
[in a new window]
|
Fig. 5.
Effect of 3'-deletion of the H-ferritin
3'-UTR on the RNA-protein complex formation. The radiolabeled
full-length or 3'-deleted transcripts prepared from AflII or
SphI-digested 3'-UTR cDNA template was incubated with
the indicated amounts of bovine serum albumin (BSA) or
cytosolic extracts from THP-1 cells as described under "Experimental
Procedures." The formation of specific RNA-protein complex was
analyzed by gel mobility shift assay.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
RNase T1 mapping of the sequence on 3'-UTR of
H-ferritin mRNA interacting with the protein factor.
Radiolabeled 3'-UTR or protected RNA fragment eluted from the
RNA-protein complex was digested with or without RNase T1 and analyzed
by sequencing gel. Asterisk indicates the protected
fragment. The sites of cleavage by RNase T1 on the 3'-UTR of H-ferritin
mRNA are indicated by arrows. The protected 22-base
sequence is underlined.
|
|

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of homoribopolymers on the formation
of the RNA-protein complex. Cytosolic extracts (20 µg) from
THP-1 cells were incubated with radiolabeled H-ferritin 3'-UTR in the
absence or presence of the indicated amounts of poly(U), poly(C), or
poly(A). After RNase T1 digestion and addition of heparin, the
formation of the RNA-protein complex was analyzed by gel mobility shift
assay.
|
|
To confirm the role of the U-rich sequence on mRNA stability, the
effects of point mutations within the poly(U) tract of the H-ferritin
3'-UTR on the RNA-protein complex formation and the stability of
chimeric transcript were examined. As shown in Fig. 8B, substitution of uridines
at positions +72 and +74 by adenines (M1) reduced the binding of the
cytosolic protein factor to 3'-UTR by ~50%. Further substitution of
uridines at positions +77, +79, +83, and +85 by adenines (M2)
completely abolished the binding. When the chimeric luciferase
constructs carrying the mutant 3'-UTRs were transfected into THP-1
cells and the stability of their transcripts was assessed, it was shown
that the mutant Luc/M1 mRNA has a calculated half-life of 7.4 ± 1.4 h, and mutant Luc/M2 mRNA has a half-life of >9 h.
Apparently, both mutant transcripts are more stable than the chimeric
transcript carrying the wild type 3'-UTR shown in Fig. 1.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 8.
Effects of mutations within the U-rich
sequence on the RNA-protein complex formation and the stability of
chimeric luciferase mRNA. A, nucleotide
substitutions within the pyrimidine-rich sequence of the H-ferritin
3'-UTR. B, gel mobility shift assay with
32P-labeled wild type (WT) or mutant
(M1 and M2) 3'-UTR. C, THP-1 cells
were transiently transfected with chimeric luciferase constructs
carrying mutant 3'-UTRs (Luc/M1 and Luc/M2). Total RNA was isolated at
different time intervals after treatment of cells with actinomycin D
(10 µg/ml) for 0, 3, 6, and 9 h. The level of luciferase
mRNA was quantified by semiquantitative RT-PCR. D,
luciferase mRNA level expressed as a percentage of the initial
value was plotted versus time after actinomycin D treatment.
Data shown are the mean of three independent experiments.
|
|
 |
DISCUSSION |
As revealed by the transient transfection experiment, the 3'-UTR
of the human H-ferritin gene placed at the 3'-end of luciferase gene
destabilized the reporter transcript by decreasing its half-life from
8.0 ± 0.5 to 4.5 ± 0.3 h in monocytic THP-1 cells.
Nevertheless, PMA treatment significantly prolonged the half-life of
the chimeric mRNA to greater than 9 h, indicating that the
3'-UTR contains a sequence determinant mediating the PMA-induced
message stabilization in these cells. Identification and sequence
analysis of this regulatory element revealed that it is pyrimidine-rich
and interacts with a novel protein factor which is present in cytoplasm
of THP-1 cells but not HeLa or hepatoma PLC cells. The restriction in
cell-type distribution is consistent with the early finding that
induction of H-ferritin gene expression by PMA is myeloid cell-specific (16). When we examined the 3'-UTRs of H-ferritin mRNAs from different species, it is clearly shown that the homologous
pyrimidine-rich sequence is present in all of them (Fig.
9), indicating that this sequence is
highly conserved and may have an important role in H-ferritin gene
expression. PMA treatment of THP-1 cells resulted in the decrease of
the protein binding to the H-ferritin 3'-UTR, suggesting that the
binding protein acts as a destabilizer. A similar phenomenon has been
reported in 3T3 cells, in which the induction of ribonucleotide
reductase R1 and R2 genes by PMA is associated with the decrease in the
binding activities of the RNA-binding proteins to their 3'-UTRs (19,
20). Likewise, a recent study on human pleural mesothelioma cells has
shown that stabilization of the urokinase receptor mRNA by PMA is
correlated with the down-regulation of the formation of a urokinase
receptor RNA-protein complex (21).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 9.
Pyrimidine-rich sequence found in the 3'-UTR
of the H-ferritin mRNA from different species.
Numbers shown refer to the distance from the stop codon.
GenBank accession numbers are indicated in
parentheses.
|
|
The competition experiment with homoribopolymers demonstrated the
importance of poly(U) within the pyrimidine-rich sequence for the
interaction with the protein factor. The correlation between protein
binding to the U-rich sequence and message stability was further
supported by the observation that mutations in some of the uridines led
to the reduction in RNA binding, but increase in the stability of
mutant chimeric luciferase mRNA. Recently, numerous studies have
demonstrated the involvement of U-rich regions in 3'-UTRs to regulate
the message stability in many mRNAs. Accumulative evidence has
revealed that the AUUUA pentamer and U-rich sequence present in 3'-UTRs
of unstable mRNAs encoding cytokines, lymphokines, oncogenes, and
growth factors plays an important role in facilitating the degradation
of their transcripts (17, 22-24). The identification of U-rich
sequences in 3'-UTRs to control the stability of mRNAs encoding
amyloid precursor and GAP-43 proteins has also been reported (25-28).
Furthermore, the expression of some RNA-binding proteins with
preferential binding activity to the U-rich region in RNA has been
shown to be implicated in neuronal development in
Drosophila, Xenopus, and mouse embryo (29-31).
Whether the protein factor binding to the H-ferritin 3'-UTR would also
interact with the U-rich region located in the 3'-UTRs of other genes
remains to be clarified.
UV cross-linking experiments revealed that the H-ferritin
3'-UTR-binding protein has a molecular size of ~43 kDa (data not shown). Recently, a number of pyrimidine tract-binding proteins which
participate in RNA splicing or belong to a family of heterogenous nuclear ribonucleoproteins have been cloned and characterized (24,
32-36). These nuclear proteins have apparent size in the ranges of
56-70 kDa and some of them exhibit preferential binding activity to
the sequence rich in U. Based on the differences in subcellular
localization, molecular size, and the restriction in cell-type origin,
the H-ferritin 3'-UTR-binding protein appears to be distinct from these
identified pyrimidine-binding proteins. Nevertheless, a recent study
has showed that a protein factor which binds to a U-rich sequence in
the 3'-UTR of GAP-43 mRNA shares sequence homology with PTB, an
identified pyrimidine tract-binding protein implicated in RNA splicing
(28). Whether the 43-kDa protein binding to the H-ferritin 3'-UTR is a
PTB-like protein is an intriguing question awaiting to be further
investigated. It is apparent that disclosure of the molecular nature of
this RNA-binding protein should provide insight into the mechanism underlying the differential regulation of H-ferritin gene expression at
the post-transcriptional level in myeloid cells.
 |
FOOTNOTES |
*
This work was supported by Grant NSC-88-2314-B-001-026 from
the National Science Council of Taiwan, Republic of China.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Div. of Cardiovascular
Research, Institute of Biomedical Sciences, Academia Sinica, Nankang,
Taipei 11529, Taiwan, ROC. Tel.: 886-2-2652-3931; Fax: 886-2-2782-9143;
E-mail: lyc@mail.ibms.sinica.edu.tw.
 |
ABBREVIATIONS |
The abbreviations used are:
H, heavy;
L, light;
PMA, phorbol 12-myristate 13-acetate;
3'-UTR, 3'-untranslated region;
RT-PCR, reverse transcriptase-polymerase chain reaction.
 |
REFERENCES |
| 1.
|
Theil, E. C.
(1987)
Annu. Rev. Biochem.
56,
289-315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Harrison, P. M.,
and Arosio, P.
(1996)
Biochim. Biophys. Acta
1275,
161-203[Medline]
[Order article via Infotrieve]
|
| 3.
|
Levi, S.,
Luzzago, A.,
Lesareni, G.,
Cozzi, A.,
Franceschinelli, F.,
Albertini, A.,
and Arosio, P.
(1988)
J. Biol. Chem.
263,
18086-18092[Abstract/Free Full Text]
|
| 4.
|
Hentze, M. W.,
Caughman, S. W.,
Rouault, T. A.,
Barriocanal, J. G.,
Dancis, A.,
Harford, J. B.,
and Klausner, R. D.
(1987)
Science
238,
1570-1573[Abstract/Free Full Text]
|
| 5.
|
Leibold, E. A.,
and Munro, H. N.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
2171-2175[Abstract/Free Full Text]
|
| 6.
|
Haile, D. J.,
Rouault, T. A.,
Harford, J. B.,
Kennedy, M. C.,
Blondin, G. A.,
Beinert, H.,
and Klausner, R. D.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
11735-11739[Abstract/Free Full Text]
|
| 7.
|
Stevens, P. W.,
Dodgson, J. B.,
and Engel, J. D.
(1987)
Mol. Cell. Biol.
7,
1751-1758[Abstract/Free Full Text]
|
| 8.
|
Torti, S. V.,
Kwak, E. L.,
Miller, S. C.,
Miller, L. L.,
Ringold, G. M.,
Myambo, K. B.,
Young, A. P.,
and Torti, F. M.
(1988)
J. Biol. Chem.
263,
12638-12644[Abstract/Free Full Text]
|
| 9.
|
Colucci-D'Amoto, L.,
Ursini, M. V.,
Colletta, G.,
Cirafici, A.,
and de Franciscis, V.
(1989)
Biochem. Biophys. Res. Commun.
165,
506-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
McCarty, G. A.,
Chan, A. K.,
Choy, B. K.,
and Wright, J. A.
(1990)
J. Biol. Chem.
265,
7539-7547[Abstract/Free Full Text]
|
| 11.
|
Wei, Y.,
Miller, S. C.,
Tsuji, Y.,
Torti, S. V.,
and Torti, F. M.
(1990)
Biochem. Biophys Res. Commun
169,
289-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Chazenbalk, G. D.,
Wadsworth, H. L.,
and Rapoport, B.
(1990)
J. Biol. Chem.
265,
666-670[Abstract/Free Full Text]
|
| 13.
|
Liau, G.,
Chan, L. M.,
and Feng, P.
(1991)
J. Biol. Chem.
266,
18819-18826[Abstract/Free Full Text]
|
| 14.
|
Chou, C.-C.,
Gatti, R. A.,
Fuller, M. F.,
Concannon, P.,
Wong, A.,
Chada, A.,
Davis, R. C.,
and Salser, W. A.
(1986)
Mol. Cell. Biol.
6,
566-573[Abstract/Free Full Text]
|
| 15.
|
Beaumont, C.,
Jain, S. K.,
Bogard, M.,
Nordmann, Y.,
and Drysdale, J.
(1987)
J. Biol. Chem.
262,
10619-10623[Abstract/Free Full Text]
|
| 16.
|
Pang, J.-H. S.,
Wu, C.-J.,
and Chau, L.-Y.
(1996)
Biochem. J.
319,
185-189
|
| 17.
|
Ross, J.
(1995)
Microbiol. Rev.
59,
423-450[Abstract/Free Full Text]
|
| 18.
|
Pang, J.-H. S.,
Jiang, M.-J.,
Chen, Y.-L.,
Wang, F.-W.,
Wang, D. L.,
Chu, S.-H.,
and Chau, L.-Y.
(1996)
J. Clin. Invest.
97,
2204-2212[Medline]
[Order article via Infotrieve]
|
| 19.
|
Chen, F. Y.,
Amara, F. M.,
and Wright, J. A.
(1993)
EMBO J.
12,
3977-3986[Medline]
[Order article via Infotrieve]
|
| 20.
|
Amara, F. M.,
Chen, F. Y.,
and Wright, J. A.
(1994)
J. Biol. Chem.
269,
6709-6715[Abstract/Free Full Text]
|
| 21.
|
Shetty, S.,
Kumar, A.,
and Idell, S.
(1997)
Mol. Cell. Biol.
17,
1075-1083[Abstract]
|
| 22.
|
Shaw, G.,
and Kamen, R.
(1986)
Cell
46,
659-667[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Brawerman, G.
(1989)
Cell
57,
9-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Morris, D. R.,
Kakegawa, T.,
Kaspar, R. L.,
and White, M. W.
(1993)
Biochemistry
32,
2931-2937[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Zaidi, S. H. E.,
Denman, R.,
and Malter, J. S.
(1994)
J. Biol. Chem.
269,
24000-24006[Abstract/Free Full Text]
|
| 26.
|
Zaidi, S. H. E.,
and Malter, J. S.
(1994)
J. Biol. Chem.
269,
24007-24013[Abstract/Free Full Text]
|
| 27.
|
Tsai, K.-C.,
Cansino, V. V.,
Kohn, D. T.,
Neve, R. L.,
and Perrone-Bizzozero, N. I.
(1997)
J. Neurosci
17,
1950-1958[Abstract/Free Full Text]
|
| 28.
|
Irwin, N.,
Baekelandt, V.,
Goritchenko, L.,
and Benowitz, L. I.
(1997)
Nucleic Acids Res
25,
1281-1288[Abstract/Free Full Text]
|
| 29.
|
Haynes, S. R.,
Cooper, M. T.,
Pype, S.,
and Stolow, D. T.
(1997)
Mol. Cell. Biol.
17,
2708-2715[Abstract]
|
| 30.
|
Peng, S. S.,
Chen, C. Y.,
Xu, N.,
and Shyu, A. B.
(1998)
EMBO J.
17,
3461-3470[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Sakakibara, S.,
Imai, T.,
Hamaguchi, K.,
Okabe, M.,
Aruga, J.,
Nakajima, K.,
Yasutomi, D.,
Nagata, T.,
Kurihara, Y.,
Uesugi, S.,
Miyata, T.,
Ogawa, M.,
Mikoshiba, K.,
and Okano, H.
(1996)
Dev. Biol.
176,
230-242[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Garcia-Blanco, M. A.,
Jamison, S. F.,
and Sharp, P. A.
(1989)
Genes Dev.
3,
1874-1886[Abstract/Free Full Text]
|
| 33.
|
Patton, J. G.,
Mayer, S. A.,
Tempst, P.,
and Nadal-Ginard, B.
(1991)
Genes Dev.
5,
1237-1251[Abstract/Free Full Text]
|
| 34.
|
Dreyfuss, G.,
Philipson, L.,
and Mattaj, I. W.
(1988)
J. Cell Biol.
106,
1419-1425[Free Full Text]
|
| 35.
|
Matunis, M. J.,
Michael, W. M.,
and Dreyfuss, G.
(1992)
Mol. Cell. Biol.
12,
164-171[Abstract/Free Full Text]
|
| 36.
|
Ghetti, A.,
Pinol-Roma, S.,
Michael, W. M.,
Morandi, C.,
and Dreyfuss, G.
(1992)
Nucleic Acids Res
20,
6910-6914
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.